Research
Hormonal
Insulin resistance can be accurately predicted using routine clinical variables (HOMA-IR, HDL, fasting insulin) without performing a hyperinsulinemic-euglycemic clamp.
You do not need a specialized clamp test to screen for insulin resistance. Ask your doctor for a fasting insulin, glucose, and HDL test. If your HOMA-IR is above 5.9, or between 2.8 and 5.9 with low HDL (<51 mg/dL), you likely have insulin resistance.
GoodSupportsHIGH confidence
We found that individual insulin resistance could be estimated with good sensitivity (89%) and specificity (67%) from the homeostasis model assessment of insulin resistance (HOMA-IR) >5.9 or 2.8, HOMA-IR <5.9 with HDL <51 mg/dL.
Why this rating
Validated using classification tree models on a training/testing split of the main cohort.
Source
Defining Insulin Resistance From Hyperinsulinemic-Euglycemic Clamps
Charmaine S. Tam et al. · Diabetes Care · 2012
DOI 10.2337/dc11-2339
cross_sectional · n=263Cited 362×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A glucose disposal rate (GDR) below 5.6 mg/kgFFM+17.7 min during a 120 mU/m2·min hyperinsulinemic-euglycemic clamp identifies insulin resistance with 75% sensitivity and 71% specificity in white populations.Good
- A glucose disposal rate (GDR) below 5.3 mg/kgFFM+17.7 min during an 80 mU/m2·min hyperinsulinemic-euglycemic clamp identifies insulin resistance with 83% sensitivity and 96% specificity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →